Lingxi Bio Drives the Future of Health Management with Continuous Data Streams through "Smart Hardware + AI Platform"

In the wave of rapid growth in the global wearable health device market, China's innovative medical company Lingxi Bio successfully held a strategic and new product launch event on January 29, themed "Continuous Protection, Reshaping the Future of Health." This launch deeply focused on medical-grade AI wearable devices and dynamic health data services, comprehensively explaining the transformative path of health monitoring shifting from the traditional "spot-check" model to a "continuous" monitoring paradigm.

Driven by the corporate mission of "Precision Medicine, Within Reach",Lingxi Bio First Systematically Proposes "Smart Hardware + AI Platform" Dual-Drive Strategy,ThroughDeep Integration of Medical-Grade Hardware Matrix with AI Algorithms, BuildPrevention-Diagnosis-Monitoring-ManagementThe full-cycle health service closed loop, marking the publicDepartmentA milestone step in the construction of the "Comprehensive Dynamic Health Management" ecosystem.

At the beginning of the press conference, Lingxi Bio CEO Peng Zhifeng unveiled the company's new strategic blueprint, "The Future is Here: Redefining the Next-Generation Paradigm of Health Monitoring with Medical-Grade AI Wearables." He pointed out that traditional health monitoring relies on intermittent "spot-check" data, which struggles to capture dynamic fluctuations in the human body. For instance, traditional blood pressure monitors and glucose meters can only capture instantaneous data, unable to reveal critical health indicators such as blood glucose fluctuation curves or nighttime blood pressure peaks, leading to overlooked risks like hidden hyperglycemia and nocturnal hypertension. Lingxi Bio’s solution achieves "full-time, full-space" protection through continuous data streams. The company aims to become China’s leading brand in precision healthcare management, focusing on a model of "independent research and development + collaborative R&D" to create a hardware product matrix covering multiple vital signs including dynamic blood pressure, blood glucose, blood oxygen, and body temperature. Combined with an AI early warning platform, this will establish a full-cycle health service loop encompassing prevention, diagnosis, monitoring, and management.

This press conference highlighted Lingxi Biotech's innovative products for different scenarios:

LingWatch Pro Flagship Dynamic Blood Pressure Watch: The first medical-grade continuous and non-invasive micro-pressure blood pressure watch in China, capable of 24-hour automatic monitoring, overcomes the limitations of traditional devices such as "white coat hypertension" and the inability to capture nighttime data.

LingRing-Dubhe-R1 "All-Vital-Signs Monitoring" Smart Ring: Integrated with five core vital sign monitoring functions: non-invasive blood glucose trend monitoring, PPG blood pressure, blood oxygen, body temperature, and heart rate variability.

LingCare SpringMini Portable Oxygen Concentrator: Weighing only 1.6kg, it achieves medical-grade oxygen concentration, providing stable oxygen supply at altitudes of 6000 meters, suitable for home, in-vehicle, and outdoor highland scenarios.

LingCare-Spring5L Oxygen Concentrator and Nebulizer Integrated Machine: Ultra-quiet design (<45dB), 24-hour continuous oxygen supply, suitable for nearly 100 million COPD patients and people with sleep apnea.

In addition,VitalSight® AI Early Warning Platform 2.0The on-site demonstration of multi-parameter fusion and 72-hour early warning simulation marks Lingxi Bio's extension from hardware to a "data + service" ecosystem. According to reports, these products fill a market gap, as traditional devices cannot simultaneously provide continuous monitoring of blood pressure, blood glucose, and blood oxygen, helping users shift from passive treatment to proactive prevention.

At the press conference, Lingxi Bio officially appointed Zhang Yuanting, an academician of the International Academy of Medical and Biological Engineering, as the chief scientist.Dr. PAI, the artificial intelligence large model independently developed by Academician Zhang Yuanting's team, will be deeply integrated into the Lingxi Health Management Platform. Through real-time learning and modeling of continuous data streams, it will generate personalized health intervention plans. This move will significantly enhance the clinical value of Lingxi products in scenarios such as chronic disease management and early identification of abnormal signs.

On site, Academician Yuan Ting Zhang also gave a cutting-edge presentation titled "Dynamic Vital Signs Monitoring: Challenges and Future of Health Engineering," analyzing from the dimensions of international trends, technological evolution, and clinical value.He emphasized that AI-driven continuous monitoring has achieved a leap from "diagnosis" to "management," and future healthcare will gradually realize "personalized AI doctors," covering the management of chronic diseases such as hypertension and cardiovascular and cerebrovascular conditions.

At the appointment ceremony of Lingxi Bio's Chief Scientist, Academician Zhang Yuanting expressed that Lingxi Bio has entered the "continuous monitoring" golden track with a forward-looking vision, accurately grasping the future trend of integrating medical-grade wearable devices with AI algorithms. He highly values the team's intelligence and industrialization determination. Both parties will join hands to scale the peak of health engineering and together define the standards and future of the next generation of global health technology.

At the same time, Lingxi Bio signed an agreement with Xinyong Technology, an innovative enterprise originating from Tsinghua University, to jointly develop the next generation of non-invasive monitoring technology. It is reported that the cooperation between the two parties has expanded to the field of handheld ultrasound instruments, aiming to incorporate richer imaging data into the continuous health management ecosystem, which will further strengthen Lingxi Bio's technical barriers in the field of medical-grade wearable devices.

In addition, Lingxi Biotech has also signed a new product launch cooperation agreement with JD Health, jointly building "continuous"Health Management Monitoring Zone." As a leading medical health platform in China, JD Health will provide Lingxi Bio with strong sales channel and user scenario support. In the future, users will be able to directly purchase various health monitoring devices from Lingxi Bio on the JD Health platform and enjoy personalized health management services based on continuous data streams.

At the subsequent roundtable forum, Academician Yuan Ting Zhang, CEO of Xinyong Technology, Yibin Li,Qiming Venture Partners Vice President Sun Motao, JD Health Medical Device Health Monitoring Head Qiao Qi, and host Peng Zhifeng engaged in a dialogue on the topic "Continuous Data Stream: Reshaping the Value and Future of Health Management."

Guests from industry, academia,From the perspectives of research and capital, the clinical value of technological breakthroughs, differences between domestic and international markets, and business models were discussed. The innovative nature and practical implementation of "comprehensive dynamic health management" based on continuous monitoring, led by Lingxi Biotech, were validated. Academician Zhang emphasized alignment with "value-based healthcare," stating that reducing healthcare costs yields the best return. Li Yibin expressed optimism about AI-driven predictive intervention services, which empower individuals with "health awareness" and a sense of "control," enhancing compliance. Sun Motao pointed out that hardware serves as the entry point, and business models will evolve from hardware sales to "data + service" subscriptions and "health outcome assurance" models integrated with insurance, indicating vast market potential. Qiao Qi believed that China's ecosystem advantages will drive resonance between demand and supply sides. Continuous data stream technology is profoundly transforming the methods and value of health management. Participants unanimously agreed that future health management will focus more on personalization and prevention. Chinese enterprises should leverage their agile innovation and ecosystem integration strengths to achieve overtaking through technological innovation and ecosystem collaboration.

At the press conference, Ren Jie, sales director of Lingxi Biotech, introduced the company's market layout both in China and overseas: focusing on e-commerce and dealer alliances in China; while taking North America and southwestern Europe as strategic highlands overseas, gradually expanding into northeastern Europe, Russian-speaking regions, as well as Southeast Asia and the Middle East.

Lingxi Bio occupies a unique niche in the health management field with its continuous data stream technology and innovative product portfolio. The company not only focuses on the advancement of technology and the practicality of products but also emphasizes building a complete health management service system through ecological cooperation. In the future, Lingxi Bio will continue to deepen its collaboration with industry, academia, research, and investment communities to promote the application and popularization of continuous data stream technology in more health scenarios.

CEO Peng Zhifeng concluded: "A continuous stream of data is converging into a wave that will reshape the future of health. Lingxi Bio is willing to work with its partners to not only define technology but also define value; to not only serve China but also contribute to the world." This press conference heralds a profound transformation in health management—from reactive to proactive.